Antiepileptic drugs with mood stabilizing properties and their relation with psychotropic drug use in institutionalized epilepsy patients with intellectual disability

Research in Developmental Disabilities

Volumn 32, Issue 6, 2011, Pages 2660-2668

  Leunissen, C L F ^a,b   de la Parra, N M ^b   Tan, I Y ^b   Rentmeester, Th W ^b   Vader, C I ^b   Veendrick Meekes, M J B M ^b   Aldenkamp, A P ^a,b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b EPILEPSY CENTER KEMPENHAEGHE   (Netherlands)

Author keywords

Drug load; Epilepsy; Intellectual disability; Mood stabilizing antiepileptic drugs; PDD DDD ratio; Psychotropic drug use

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CARBAMAZEPINE; LAMOTRIGINE; MOOD STABILIZER; PSYCHOTROPIC AGENT; VALPROIC ACID;

ADOLESCENT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG CHOICE; DRUG USE; EPILEPSY; FEMALE; HUMAN; INTELLECTUAL IMPAIRMENT; INTENTION TO TREAT ANALYSIS; INTERMETHOD COMPARISON; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; RETROSPECTIVE STUDY; SEX DIFFERENCE; SEX RATIO;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CARBAMAZEPINE; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; EPILEPSY; FEMALE; HUMANS; INTELLECTUAL DISABILITY; MALE; MIDDLE AGED; MOOD DISORDERS; PSYCHOTROPIC DRUGS; RETROSPECTIVE STUDIES; TRIAZINES; VALPROIC ACID; YOUNG ADULT;

EID: 80053634995     PISSN: 08914222     EISSN: 18733379     Source Type: Journal    
DOI: 10.1016/j.ridd.2011.06.007     Document Type: Article

References (34)

1. The American Association on Intellectual and Developmental Disabilities [AAIDD] The AAMR definition of mental retardation 2002, [cited 2007 September 07; online] Available from: URL: http://www.aaidd.org/Policies/pdf/definitionofMR.pdf.
2. Arshad S., Winterhalder R., Underwood L., Kelesidi K., Chaplin E., Kravariti E., et al. Epilepsy and intellectual disability: Does epilepsy increase the likelihood of co-morbid psychopathology?. Research in Developmental Disabilities 2011, 32(1):353-357.
3. Beghi E., Cornaggia C., the RESt-1 Group Morbidity and accidents in patients with epilepsy: Results of a European Cohort Study. Epilepsia 2002, 43(9):1076-1083.
4. Connor D.F., Ozbayrak K.R., Harrison R.J., Melloni R.H. Prevalence and patterns of psychotropic and anticonvulsant medication use in children and adolescents referred to residential treatment. Journal of Child Adolescent Psychopharmacology 1998, 8(1):27-38.
5. Cooper S.A., Smiley E., Morrison J., Williamson A., Allan L. Mental ill-health in adults with intellectual disabilities: Prevalence and associated factors. The British Journal of Psychiatry 2007, 190(January):27-35.
6. de Klerk M.M.Y. Hoe vaak komt een verstandelijke handicap voor? 2004, [cited 2007 November 26; online] Available from: URL: http://www.rivm.nl/vtv/object_document/o2068n17541.html [Dutch].
7. Deb S., Chaplin R., Sohanpal S., Unwin G., Soni R., Lenotre L. The effectiveness of mood stabilizers and antiepileptic medication for the management of behaviour problems in adults with intellectual disability: A systematic review. Journal of Intellectual Disability Research 2008, 52(2):107-113.
8. Ettinger A.B. Psychotropic effects of antiepileptic drugs. Neurology 2006, 67(1):1916-1925.
9. Gaitatzis A., Trimble M.R., Sander J.W. The psychiatric comorbidity of epilepsy. Acta Neurologica Scandinavica 2004, 110(4):207-220.
10. Gajwani P., Forsthoff A., Muzina D., Amann B., Gao K., Elhaj O., et al. Antiepileptic drugs in mood-disordered patients. Epilepsia 2005, 46(Suppl. 4):38-44.
11. Hancock R.D., Weber S.L., Kaza R., Her K.S. Changes in psychotropic drug use in long-term residents of an ICF/MR facility. American Journal of Mental Retardation 1991, 96(2):137-141.
12. Johannessen L.C. Antiepileptic drugs in nonepilepsy disorders: Relations between mechanisms of action and clinical efficacy. CNS Drugs 2008, 22:27-47.
13. Ketter T.A., Post R.M., Theodore W.H. Positive and negative psychotropic effects of antiepileptic drugs in patients with seizure disorders. Neurology 1999, 53(Suppl. 2):S53-S67.
14. Kiernan C., Reeves D., Alborz A. The use of antipsychotic drugs with adults with learning disabilities and challenging behaviour. Journal of Intellectual Disability Research 1995, 39(4):263-274.
15. Lhatoo S.D., Sander J.W.A.S. The epidemiology of epilepsy and learning disabilities. Epilepsia 2001, 42(Suppl. 1):6-9.
16. Lott I.T., McGregor M., Engelman L., Touchette P., Tournay A., Sandman C., et al. Longitudinal prescribing patterns for psychoactive medications in community-based individuals with developmental disabilities: Utilization of pharmacy records. Journal of Intellectual Disability Research 2004, 48(6):563-571.
17. Matsuura M., Oana Y., Kato M., Kawana A., Kan R., Kubota H., et al. A multicenter study on the prevalence of psychiatric disorders among new referrals for epilepsy in Japan. Epilepsia 2003, 44(1):107-114.
18. McGrother C.W., Bhaumik S., Thorp C.F., Hauck A., Branford D., Watson J.M. Epilepsy in adults with intellectual disabilities: Prevalence, associations and service implications. Seizure 2006, 15(6):376-386.
19. Reijs R., Aldenkamp A.P., de Krom M. Mood effects of antiepileptic drugs. Epilepsy Behaviour 2004, 5(Suppl. 1):S66-S76.
20. Schmitz B. Effects of antiepileptic drugs on mood and behaviour. Epilepsia 2006, 47(Suppl. 2):28-33.
21. Selai C., Bannister D., Trimble M. Antiepileptic drugs and the regulation of mood and quality of life (QOL): The evidence from epilepsy. Epilepsia 2005, 46(Suppl. 4):50-57.
22. Singh N.N., Ellis C.R., Wechsler H. Psychopharmacoepidemiology of mental retardation: 1966 to 1995. Journal of Child and Adolescent Psychopharmacoly 1997, 7(4):255-266.
23. Spreat S., Conroy J.W., Jones J.C. Use of psychotropic medication in Oklahoma: A statewide survey. American Journal of Mental Retardation 1997, 102(1):80-85.
24. Spreat S., Conroy J. Use of psychotropic medications for persons with mental retardation who live in Oklahoma nursing homes. Psychiatric Services 1998, 49(4):510-512.
25. Stenbom Y., Tonnby B., Hagberg B. Lamotrigine in Rett syndrome: Treatment experience from a pilot study. European Child & Adolescent Psychiatry 1998, 7(1):49-52.
26. Stolker J.J., Heerdink E.R., Leufkens H.G.M., Clerkx M.G.M., Nolen W.A. Determinants of multiple psychotropic drug use in patients with mild intellectual disabilities or borderline intellectual functioning and psychiatric or behavioural disorders. General Hospital Psychiatry 2001, 23(6):345-349.
27. Stolker J.J., Koedoot P.J., Heerdink E.R., Leufkens H.G.M., Nolen W.A. Psychotropic drug use in intellectually disabled group-home residents with behavioural problems. Pharmacopsychiatry 2002, 35(1):19-23.
28. Turky A., Felce D., Jones G., Kerr M. A prospective study of psychiatric disorders in adults with epilepsy and intellectual disability. Epilepsia 2011, [Epub ahead of print].
29. van den Broek M., Beghi E. Morbidity in patients with epilepsy: Type and complications: A European cohort study. Epilepsia 2004, 45(1):71-76.
30. van Schrojenstein Lantman-de Valk H.M.J., Kessels A.G.H., Haveman M.J., Maaskant M.A., Urlings H.F.J., van den Akker M. Drug use by mentally handicapped persons in institutions and family-replacing residential facilities. Nederlnads Tijdschrift voor Geneeskunde 1995, 139(21):1083-1088. [Dutch].
31. van Waarde J.A., Stolker J.J., Van H.L. Psychiatric consultation and treatment for mentally handicapped persons exhibiting behavioural changes. Nederlands Tijdschrift voor Geneeskunde 1999, 143(36):1801-1804. [Dutch].
32. Veendrick M.J.B., Aldenkamp A.P., Tan I.Y. Citalopram in mentally retarded epilepsy patients with anxiety disorder. Epilepsia 2004, 45(Suppl. 3):166.
33. Verhoeven W.M.A., Tuinier S. Verstandelijk gehandicapten: op weg naar een medisch-specialistische emancipatie. Tijdschrift voor Psychiatrie 2003, 45(11):697-700. [Dutch].
34. WHO Collaborating Centre for Drug Statistics Methodology ATC/DDD index 2007 2007, [cited 2007 October 19; online] Available from: URL: http://www.whocc.no/atcddd/.